《中国男性乳腺癌临床诊治实践指南(2023 版)》 诊疗解读  

Interpretation of Clinical practice China guidelines for male breast cancer(2023 edition)

作　　者：张雅兰 刘帆[1] 王彦伟 郭琎祎 宋爱琳[1,2,3] Zhang Yalan;Liu Fan;Wang Yanwei;Guo Jinyi;Song Ailin(The Second Clinical Medical School,Lanzhou University,Lanzhou 730030,China;General Surgery Department,The Second Hospital of Lanzhou University,Lanzhou 730030,China;Key Laboratory of Environmental Oncology of Gansu Province,The Second Hospital of Lanzhou University,Lanzhou 730030,China)

机构地区：[1]兰州大学第二临床医学院,甘肃兰州730030 [2]兰州大学第二医院普外科,甘肃兰州730030 [3]兰州大学第二医院甘肃省环境肿瘤学重点实验室,甘肃兰州730030

出　　处：《兰州大学学报（医学版）》2023年第11期72-78,94,共8页Journal of Lanzhou University（Medical Sciences）

基　　金：北京健康促进会“中国乳腺外科青年医师研究”奖励基金资助项目(2020-CHPASLP);兰州大学第二医院“萃英学子科研培育”计划资助项目(CYXZ2021-40)。

摘　　要：男性乳腺癌发病罕见,预后较差,以往只能参考女性乳腺癌相关指南进行诊疗。中华医学会外科学分会乳腺外科学组共同制定的《中国男性乳腺癌临床诊治实践指南(2023版)》于2023年2月4日首次发布,该指南结合中国国情对男性乳腺癌管理的各个环节进行了详细阐述并作出相应推荐,是国内首部男性乳腺癌诊疗指南。本文通过查阅相关文献,对该指南中男性乳腺癌的诊疗内容进行详细解读。Male breast cancer is rare and has a poor prognosis.Prospective data in the management of male breast cancer are lacking,and the majority of treatment strategies are adopted from the established guidelines for female breast cancer.The Clinical Practice China Guidelines for Male Breast Cancer(2023 edition)jointly formulated by the Chinese Society of Breast Surgery,Chinese Society of Surgery and Chinese Medical Association was first published on February 4,2023.The guidelines elaborate and make recommendations on various aspects of male breast cancer management in accordance with the Chinese national status.This article aimed at making a detailed interpretation of the diagnosis and treatment contents of male breast cancer in the guidelines by referring to relevant literature.

关 键 词：男性乳腺癌 诊断 治疗 指南 解读 

分 类 号：R737.9[医药卫生—肿瘤]